The Latin America, Middle East and Africa Interventional Oncology Market is expected to witness market growth of 9.9% CAGR during the forecast period (2022-2028).
IO has proven to be especially effective in the treatment of pain in cancer patients, the huge majority of whom are unable to get enough relief from pain medications and radiotherapy. About90% of cancer patients experience pain during their treatment, and nearly half of those with advanced cancer experience mild to severe pain. Minimally invasive IO procedures such as ablation,neurolysis, bone and vertebral augmentation are all effective palliative treatments for cancer pain. These treatments act on the tumour directly or indirectly, as in the case of regional anaesthesia from neurolysis, by limiting its growth and stabilising the lesion.
The United Arab Emirates (UAE) has one of the quicker economies in the world, which has resulted in a rise in noncommunicable diseases such as cancer. Although screening and early diagnosis efforts that seem to be far from objective coverage of the targeted respondents, the number of cases and death have been rising in the UAE over the years. The UAE's cancer control plan is being developed in accordance with WHO and EMRO guidelines, with specific objectives and goals in mind. The goals are to fight cancer, reduce its occurrence, control mortality, and enhance cancer patients' outcomes and quality of life. Improved public health education, early detection, prevention,fast diagnosis,continuity of care, treatment facilitation, workforce training, performance evaluation, and research are also priorities.
After cardiovascular illnesses and trauma, cancer is the third largest cause of mortality in the United Arab Emirates (UAE). The death ratio in the United Arab Emirates is 0.39, which is similar to other developed nations. Owing to the rise in the case of cancer, the regional interventional oncology market is expected to augment in the forecast period.
The Brazil market dominated the LAMEA Interventional Oncology Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $51.3 million by 2028. The Argentina market is experiencing a CAGR of 10.4% during (2022-2028). Additionally, The UAE market is expected to exhibit a CAGR of 9.6% during (2022-2028).
Based on Cancer Type, the market is segmented into Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Prostate Cancer, Bone Metastasis, and Others. Based on Product Type, the market is segmented into Embolization Devices, Ablation Devices, and Support Devices. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers, and Research & Academic Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Teleflex, Inc., Cook Medical, Inc. (Cook Group), Medtronic PLC, Terumo Corporation , Johnson & Johnson (Johnson & Johnson Services, Inc.), Becton, Dickinson and Company, AngioDynamics, Inc., Merit Medical Systems, Inc., and HealthTronics, Inc. (Altaris Capital Partners, LLC)
By Cancer Type
IO has proven to be especially effective in the treatment of pain in cancer patients, the huge majority of whom are unable to get enough relief from pain medications and radiotherapy. About90% of cancer patients experience pain during their treatment, and nearly half of those with advanced cancer experience mild to severe pain. Minimally invasive IO procedures such as ablation,neurolysis, bone and vertebral augmentation are all effective palliative treatments for cancer pain. These treatments act on the tumour directly or indirectly, as in the case of regional anaesthesia from neurolysis, by limiting its growth and stabilising the lesion.
The United Arab Emirates (UAE) has one of the quicker economies in the world, which has resulted in a rise in noncommunicable diseases such as cancer. Although screening and early diagnosis efforts that seem to be far from objective coverage of the targeted respondents, the number of cases and death have been rising in the UAE over the years. The UAE's cancer control plan is being developed in accordance with WHO and EMRO guidelines, with specific objectives and goals in mind. The goals are to fight cancer, reduce its occurrence, control mortality, and enhance cancer patients' outcomes and quality of life. Improved public health education, early detection, prevention,fast diagnosis,continuity of care, treatment facilitation, workforce training, performance evaluation, and research are also priorities.
After cardiovascular illnesses and trauma, cancer is the third largest cause of mortality in the United Arab Emirates (UAE). The death ratio in the United Arab Emirates is 0.39, which is similar to other developed nations. Owing to the rise in the case of cancer, the regional interventional oncology market is expected to augment in the forecast period.
The Brazil market dominated the LAMEA Interventional Oncology Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $51.3 million by 2028. The Argentina market is experiencing a CAGR of 10.4% during (2022-2028). Additionally, The UAE market is expected to exhibit a CAGR of 9.6% during (2022-2028).
Based on Cancer Type, the market is segmented into Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Prostate Cancer, Bone Metastasis, and Others. Based on Product Type, the market is segmented into Embolization Devices, Ablation Devices, and Support Devices. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers, and Research & Academic Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Teleflex, Inc., Cook Medical, Inc. (Cook Group), Medtronic PLC, Terumo Corporation , Johnson & Johnson (Johnson & Johnson Services, Inc.), Becton, Dickinson and Company, AngioDynamics, Inc., Merit Medical Systems, Inc., and HealthTronics, Inc. (Altaris Capital Partners, LLC)
Scope of the Study
Market Segments Covered in the Report:
By Cancer Type
- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Breast Cancer
- Prostate Cancer
- Bone Metastasis
- Others
- Embolization Devices
- Ablation Devices
- Support Devices
- Hospitals
- Ambulatory Surgery Centers
- Research & Academic Institutes
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Boston Scientific Corporation
- Teleflex, Inc.
- Cook Medical, Inc. (Cook Group)
- Medtronic PLC
- Terumo Corporation
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Becton, Dickinson and Company
- AngioDynamics, Inc.
- Merit Medical Systems, Inc.
- HealthTronics, Inc. (Altaris Capital Partners, LLC)
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Interventional Oncology Market by Cancer Type
Chapter 4. LAMEA Interventional Oncology Market by Product Type
Chapter 5. LAMEA Interventional Oncology Market by End User
Chapter 6. LAMEA Interventional Oncology Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Teleflex, Inc.
- Cook Medical, Inc. (Cook Group)
- Medtronic PLC
- Terumo Corporation
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Becton, Dickinson and Company
- AngioDynamics, Inc.
- Merit Medical Systems, Inc.
- HealthTronics, Inc. (Altaris Capital Partners, LLC)
Methodology
LOADING...
